Anny H. Xiang

Anny H. Xiang

Auto-generated profile, based on publicly available information

Anny H. Xiang

Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States of America

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2011 in Obesity
Verified
Journal Article
Open access
PDF file
RBRichard N. Bergman
Richard N. Bergman
DSDarko Stefanovski
Darko Stefanovski
TBThomas A. Buchanan
Thomas A. Buchanan
ASAnne E. Sumner
Anne E. Sumner
JRJames C. Reynolds
James C. Reynolds
RWRichard M. Watanabe
Richard M. Watanabe
Obesity is a growing problem in the United States and throughout the world. It is a risk factor for many chronic diseases. The BMI has been used to assess body fat for almost 200 years. BMI is known to be of limited accuracy, and is different for males and females with similar %body adiposity. Here, we define an alternative parameter, the body adiposity index (BAI = ((hip circumference)/((height)1.5)–18)). The BAI can be used to reflect %body fat for adult men and women of differing ethnicities without numerical correction. We used a population study, the “BetaGene” study, to develop the new index of body adiposity. %Body fat, as measured by the dual‐energy X‐ray absorptiometry (DXA), was used as a “gold standard” for validation. Hip circumference (R = 0.602) and height (R = −0.524) are strongly correlated with %body fat and therefore chosen as principal anthropometric measures on which we base BAI. The BAI measure was validated in the “Triglyceride and Cardiovascular Risk in African‐Americans (TARA)” study of African Americans. Correlation between DXA‐derived %adiposity and the BAI was R = 0.85 for TARA with a concordance of C_b = 0.95. BAI can be measured without weighing, which may render it useful in settings where measuring accurate body weight is problematic. In summary, we have defined a new parameter, the BAI, which can be calculated from hip circumference and height only. It can be used in the clinical setting even in remote locations with very limited access to reliable scales. The BAI estimates %adiposity directly.

1 March 2005 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
TBThomas A. Buchanan
Thomas A. Buchanan
AXAnny H. Xiang
Anny H. Xiang
Gestational diabetes mellitus (GDM) is defined as glucose intolerance of various degrees that is first detected during pregnancy. GDM is detected through the screening of pregnant women for clinical risk factors and, among at-risk women, testing for abnormal glucose tolerance that is usually, but not invariably, mild and asymptomatic. GDM appears to result from the same broad spectrum of physiological and genetic abnormalities that characterize diabetes outside of pregnancy. Indeed, women with GDM are at high risk for having or developing diabetes when they are not pregnant. Thus, GDM provides a unique opportunity to study the early pathogenesis of diabetes and to develop interventions to prevent the disease.

3 July 2012 in Nature Reviews Endocrinology
Verified
Journal Article
Open access
PDF file
TBThomas A. Buchanan
Thomas A. Buchanan
AXAnny H. Xiang
Anny H. Xiang
KPKathleen A. Page
Kathleen A. Page
Gestational diabetes mellitus is one of the most common medical complications of pregnancy. The disease has important health implications for mother and child. This Review discusses current evidence for the importance of gestational diabetes mellitus, opportunities to reduce risk to mother and child and recommendations for clinical care. Gestational diabetes mellitus (GDM) carries a small but potentially important risk of adverse perinatal outcomes and a long-term risk of obesity and glucose intolerance in offspring. Mothers with GDM have an excess of hypertensive disorders during pregnancy and a high risk of developing diabetes mellitus thereafter. Diagnosing and treating GDM can reduce perinatal complications, but only a small fraction of pregnancies benefit. Nutritional management is the cornerstone of treatment; insulin, glyburide and metformin can be used to intensify treatment. Fetal measurements complement maternal glucose monitoring in the identification of pregnancies that require such intensification. Glucose testing shortly after delivery can stratify the short-term diabetes risk in mothers. Thereafter, annual glucose and HbA1c testing can detect deteriorating glycaemic control, a harbinger of future diabetes mellitus, usually type 2 diabetes mellitus. Interventions that mitigate obesity or its metabolic effects are most potent in preventing or delaying diabetes mellitus. Lifestyle modification is the primary approach; use of medications for diabetes prevention after GDM remains controversial. Family planning enables optimization of health in subsequent pregnancies. Breastfeeding may reduce obesity in children and is recommended. Families should be encouraged to help children adopt lifestyles that reduce the risk of obesity.

14 April 2015 in JAMA
Verified
Journal Article
Open access
PDF file
AXAnny H. Xiang
Anny H. Xiang
XWXinhui Wang
Xinhui Wang
MMMayra P. Martinez
Mayra P. Martinez
JWJohanna C. Walthall
Johanna C. Walthall
ECEdward S. Curry
Edward S. Curry
DGDarios Getahun
Darios Getahun
This cohort study reports that exposure to maternal gestational diabetes mellitus diagnosed by 26 weeks was associated with risk of autism spectrum disorders in

1 February 2000 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
USUte M. Schaefer-Graf
Ute M. Schaefer-Graf
TBThomas A. Buchanan
Thomas A. Buchanan
AXAnny Xiang
Anny Xiang
GSGiuliana Songster
Giuliana Songster
MMMartin Montoro
Martin Montoro
SKSiri L. Kjos
Siri L. Kjos

1 October 2024 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
AXAnny H. Xiang
Anny H. Xiang
MMMayra P. Martinez
Mayra P. Martinez
TCTing Chow
Ting Chow
SCSarah A. Carter
Sarah A. Carter
SNSonya Negriff
Sonya Negriff
SKSid Kumar
Sid Kumar
Importance: Data from surveys show increased mental health disorders in youths. However, little is known about clinical diagnosis over time.Objective: To assess the incidence, prevalence, and changes from 2017 to 2021 for depression and anxiety diagnosed clinically among children, adolescents, and young adults and to identify potential disparities.Design, Setting, and Participants: This cohort study included approximately 1.7 million individuals aged 5 to 22 years in Southern California. Data were extracted from electronic medical records; International Statistical Classification of Diseases, Tenth Revision (ICD-10), codes were used to identify depression and/or anxiety diagnosis for each study year from January 1, 2017, to December 31, 2021. Rates were stratified by age, gender, race and ethnicity, estimated household income, weight status, and comorbidity history. Changes over time and association with these variables were assessed using Poisson regression. Data were analyzed between June 1, 2022, and November 29, 2023.Main Outcomes and Measures: Clinical diagnosis of (1) depression and (2) anxiety without a depression diagnosis using ICD-10 codes.Results: Among the 1.7 million participants, mean (SD) age was approximately 14 (5) years, and 51% were male. In terms of race and ethnicity for each study year, approximately 50% of participants were Hispanic; 8%, non-Hispanic Asian; 8%, non-Hispanic Black; and 23%, non-Hispanic White. From 2017 to 2021, depression diagnosis increased by 55.6% (from 1.35% to 2.10%) for incidence and 60.0% (from 2.55% to 4.08%) for prevalence; anxiety without depression diagnosis increased by 31.1% (from 1.77% to 2.32%) for incidence and 35.2% (from 3.13% to 4.22%) for prevalence (P < .001 for trend). The increases in rates were higher during the COVID-19 pandemic (2020-2021) than before the pandemic (2017-2019), except for depression incidence. Rates increased across all subgroups. Rates were highest for subgroups aged 14 to 17 and 18 to 22 years; female participants; those of non-Hispanic American Indian or Alaska Native, non-Hispanic White, or multiple races or ethnicities; and subgroups with higher household income, obesity (and underweight for anxiety without depression), or comorbidities. Among these factors, age was the most important factor for depression diagnosis, whereas weight status was the most important factor for anxiety without depression diagnosis.Conclusions and Relevance: This cohort study, using electronic medical record data from a large integrated health care system, found an increase in clinically diagnosed depression from 2017 to 2021, with a higher increase during the COVID-19 pandemic and higher rates in some subgroups. Equally important, this study identified high rates and an increase in clinical diagnosis of anxiety without a depression diagnosis. These results support the increased need in public health and health care effort to combat the mental health crisis in youths.